Study: NCT02600741

Intervention type: OTHER
Intervention: Caregiver psycho-education and skills training
Description: Caregivers will receive up to 16 sessions of study-provided caregiver psycho-education and skills training sessions they are able to attend within a 6-month period.

Intervention type: OTHER
Intervention: Caregiver support available at the study site
Description: Caregivers will receive whatever caregiver support that is customarily available at the study site, if any.

Intervention type: DRUG
Intervention: Paliperidone palmitate
Description: Patients enrolled in this study will continue to receive routine treatment of paliperidone palmitate, as directed by their treating physician.

Intervention type: DRUG
Intervention: Paliperidone palmitate
Description: Patients enrolled in this study will continue to receive routine treatment of paliperidone palmitate, as directed by their treating physician.

Intervention type: DRUG
Intervention: Chlorpromazine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Chlorpromazine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Droperidol
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Droperidol
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Fluphenazine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Fluphenazine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Haloperidol
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Haloperidol
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Loxapine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Loxapine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Perphenazine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Perphenazine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Pimozide
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Pimozide
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Prochlorperazine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Prochlorperazine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Thiothixene
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Thiothixene
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Thioridazine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Thioridazine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Trifluoperazine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Trifluoperazine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Aripiprazole
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Aripiprazole
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Asenapine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Asenapine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Clozapine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Clozapine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Iloperidone
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Iloperidone
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Olanzapine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Olanzapine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Paliperidone
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Paliperidone
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Quetiapine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Quetiapine
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Risperidone
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Risperidone
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Ziprasidone
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.

Intervention type: DRUG
Intervention: Ziprasidone
Description: Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.